TargetBeta
CD24
CD24 molecule · also CD24A · CD molecules
2 programs in company-led studies act on CD24, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-CD24 Monoclonal Antibody PHST001rule | Pheast Therapeutics | – | phase 1 | 11 running | – | NCIt |
| Anti-CD24/Anti-CD3 Bispecific Antibody ONC-783rule | OncoC4 | – | phase 1 | 11 running | CD3E | NCIt |
Also acted on by the same programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 1, 2027Anti-CD24/Anti-CD3 Bispecific Antibody ONC-783 · OncoC4 · phase 1 · NCT07408258
- Apr 2029Anti-CD24 Monoclonal Antibody PHST001 · Pheast Therapeutics · phase 1 · NCT06840886
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.